

HR 4369

National Centers of Excellence in Advanced and Continuous Pharmaceutical Manufacturing Act of 2021

Congress: 117 (2021–2023, Ended)

Chamber: House

Policy Area: Health

Introduced: Jul 6, 2021

Current Status: Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and

Latest Action: Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Oct 20, 2021)

Official Text: <https://www.congress.gov/bill/117th-congress/house-bill/4369>

Sponsor

Name: Rep. Pallone, Frank, Jr. [D-NJ-6]

Party: Democratic • **State:** NJ • **Chamber:** House

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Guthrie, Brett [R-KY-2]	R · KY		Jul 6, 2021

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Reported by	Jul 15, 2021
Health, Education, Labor, and Pensions Committee	Senate	Referred To	Oct 20, 2021

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
117 S 2589	Related bill	Aug 3, 2021: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Summary (as of Oct 19, 2021)

National Centers of Excellence in Advanced and Continuous Pharmaceutical Manufacturing Act of 2021

This bill directs the Food and Drug Administration (FDA) to designate qualified institutions of higher education (or consortia of such institutions) as National Centers of Excellence in Advanced and Continuous Pharmaceutical Manufacturing and to provide grants to the centers. Each designated center must conduct research on advanced and continuous pharmaceutical manufacturing technologies and must share information from such research with the FDA. (Currently, most drug production involves batch manufacturing, which typically takes longer than continuous manufacturing processes.)

Actions Timeline

- **Oct 20, 2021:** Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- **Oct 19, 2021:** Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 117-151.
- **Oct 19, 2021:** Placed on the Union Calendar, Calendar No. 111.
- **Oct 19, 2021:** Mr. Pallone moved to suspend the rules and pass the bill, as amended.
- **Oct 19, 2021:** Considered under suspension of the rules. (consideration: CR H5645-5647)
- **Oct 19, 2021:** DEBATE - The House proceeded with forty minutes of debate on H.R. 4369.
- **Oct 19, 2021:** At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
- **Oct 19, 2021:** Considered as unfinished business. (consideration: CR H5662-5663)
- **Oct 19, 2021:** Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 368 - 56 (Roll no. 318).(text: CR H5645-5647)
- **Oct 19, 2021:** On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 368 - 56 (Roll no. 318). (text: CR H5645-5647)
- **Oct 19, 2021:** Motion to reconsider laid on the table Agreed to without objection.
- **Oct 19, 2021:** The title of the measure was amended. Agreed to without objection.
- **Jul 21, 2021:** Committee Consideration and Mark-up Session Held.
- **Jul 21, 2021:** Ordered to be Reported (Amended) by Voice Vote.
- **Jul 15, 2021:** Subcommittee Consideration and Mark-up Session Held.
- **Jul 15, 2021:** Forwarded by Subcommittee to Full Committee (Amended) by Voice Vote .
- **Jul 7, 2021:** Referred to the Subcommittee on Health.
- **Jul 6, 2021:** Introduced in House
- **Jul 6, 2021:** Referred to the House Committee on Energy and Commerce.